{"id":"NCT00147199","sponsor":"United Therapeutics","briefTitle":"Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)","officialTitle":"TRIUMPH I: Double Blind Placebo Controlled Clinical Investigation Into the Efficacy and Tolerability of Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-06","primaryCompletion":"2007-10","completion":"2007-10","firstPosted":"2005-09-07","resultsPosted":"2013-08-12","lastUpdate":"2024-01-02"},"enrollment":235,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Hypertension"],"interventions":[{"type":"DRUG","name":"Inhaled treprostinil","otherNames":["Tyvaso"]},{"type":"DRUG","name":"Placebo inhalation solution","otherNames":["Placebo"]}],"arms":[{"label":"Inhaled treprostinil","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a double-blind placebo-controlled clinical investigation into the efficacy and tolerability of inhaled treprostinil in patients with severe pulmonary arterial hypertension. The primary outcome is the change in 6-minute walk distance from baseline to week 12.","primaryOutcome":{"measure":"Peak 6-minute Walk Distance","timeFrame":"12 weeks","effectByArm":[{"arm":"Inhaled Treprostinil","deltaMin":366,"sd":null},{"arm":"Placebo","deltaMin":360,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.00044"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":30,"countries":["United States","Austria","Belgium","France","Germany","Ireland","Israel","Italy","Spain","United Kingdom"]},"refs":{"pmids":["20430262"],"seeAlso":["http://www.phassociation.org"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":115},"commonTop":["cough","headache","dizziness","nausea","throat irritation"]}}